Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15607956 | 0.92 | CA1 (0.35) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL15607957 | 0.91 | CA1 (0.34) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL16375323 | 0.88 | KMT2A (0.34) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL16375023 | 0.83 | LMNA (0.37) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL16375312 | 0.81 | ERO1A (0.34) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL15607955 | 0.80 | KMT2A (0.35) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL15607954 | 0.79 | KMT2A (0.34) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL16375032 | 0.78 | F2 (0.33) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL16375031 | 0.77 | KMT2A (0.37) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL16375313 | 0.77 | EGFR (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | CA12 300/4885CA1 289/4885CA2 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.